Fosfomycin for treating Escherichia coli UTIs: Results from a tertiary hospital

Urinary tract infections (UTIs) arise due to the infiltration of microorganisms into the urinary system. The rising incidence of antibiotic resistance among UTI pathogens has narrowed the range of effective treatment options. Fosfomycin has been recognized as a potential alternative in the face of increasing resistance. This research focuses on evaluating the in vitro effectiveness of Fosfomycin against gram-negative bacteria isolated from urinary tract infections (UTIs) This retrospective study was carried out at the tertiary care hospital in Vadodara, Gujarat from 1 Jan 2022 to 31 Oct 2022. Out of 256 urine cultures that tested positive for microorganisms, 125 isolates (62.8%) were identified as and were included in the study. Standard laboratory techniques were used for bacterial identification, and the VITEK 2 compact system was employed for antimicrobial sensitivity testing. The sensitivity of Fosfomycin was assessed using the disc diffusion technique with a 200 µg disc (Himedia), and the results were interpreted by measuring the zone of inhibition. Fosfomycin showed a sensitivity rate of 96% against . Among extended-spectrum beta-lactamase (ESBL)-producing strains, Fosfomycin demonstrated a sensitivity rate of 91.4%. Fosfomycin presents a valuable option for treating UTIs, particularly those caused by , including strains that produce ESBLs.